alpha-d-lactose monohydrate
Small moleculeexperimental
Emtricitabine/rilpivirine/tenofovir, sold under the brand name Complera among others, is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the US Food and Drug Administration (FDA) in August 2011, and by the European Medicines Agency in November 2011, for patients who have not previously been treated for HIV. It is available as a once-a-day single tablet. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
3
Earliest trial started Dec 1, 2012 (NCT01715636)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- excipientOTHER
excipient other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
Also known as
- alpha-d-lactose monohydrate
- eviplera
- eviplera
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02529059 | Phase 4 | Nov 1, 2015 | Gilead Sciences, St Stephens Aids Trust |
| NCT02308332 | Phase 4 | Feb 1, 2015 | Gilead Sciences, Utrecht University |
| NCT01796431 | Phase 1 | Mar 1, 2013 | St Stephens Aids Trust |
| NCT01715636 | Phase 4 | Dec 1, 2012 | St. Vincent's Hospital-Manhattan |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 2 | 0 | 1 | 2015 |
| St Stephens Aids Trust | Academic/Hospital | 2 | 2 | 2 | 2013 |
| St. Vincent's Hospital-Manhattan | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Utrecht University | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1